Floatz logo

Adagrasib

KRAS Activating Mutation

Verastem, Inc.Small moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the KRAS Activating Mutation cohort.

Asset / SponsorPhaseRating
Avutometinib
Verastem, Inc.
Phase 2BB
Defactinib
Verastem, Inc.
Phase 2BB
Carboplatin
Shirish M Gadgeel
Phase 2CCC
Durvalumab
Shirish M Gadgeel
Phase 2CCC
Sotorasib
Verastem, Inc.
Phase 1/2CCC
Ulixertinib
D

Same molecule, other indications

Adagrasib is also rated in:

lung cancerDormant
BB
Indicative ·
64 / 100
View asset →
metastatic malignant neoplasmDormant
B
Indicative ·
58 / 100
View asset →
cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →